Figure 3.
Effect of combined treatment on early-, middle-, and late-stage LG. (A) Representative immunofluorescence micrographs demonstrating VEGFR-2 and VEGFR-3 combined blockade significantly inhibited both early- and middle-stage but not late-stage LG. Scale bars, 100 μm. (B) Summarized data from repetitive experiments. ***P < 0.001; *P < 0.05. n.s., not significant.